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There is a high prevalence of cannabis use reported in non-affective psychosis. Early prospective 
longitudinal studies conclude that cannabis use is a risk factor for psychosis, and neurochemical 
studies on cannabis have suggested potential mechanisms for this effect. Recent advances in 
the field of neuroscience and genetics may have important implications for our understanding 
of this relationship. Importantly, we need to better understand the vulnerability × cannabis
interaction to shed light on the mediators of cannabis as a risk factor for psychosis. Thus, the 
present study reviews recent literature on several variables relevant for understanding the
relationship between cannabis and psychosis, including age of onset, cognition, brain functioning, 
family history, genetics, and neurological soft signs (NSS) in non-affective psychosis. Compared 
with non-using non-affective psychosis, the present review shows that there seem to be fewer 
stable cognitive deficits in patients with cannabis use and psychosis, in addition to fewer NSS 
and possibly more normalized brain functioning, indicating less neurobiological vulnerability for 
psychosis. There are, however, some familiar and genetic vulnerabilities present in the cannabis 
psychosis group, which may influence the cannabis pathway to psychosis by increasing sensitivity 
to cannabis. Furthermore, an earlier age of onset suggests a different pathway to psychosis in 
the cannabis-using patients. Two alternative vulnerability models are presented to integrate these 
seemingly paradoxical findings
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IntroductIon
Prevalence and clInIcal ImPlIcatIons
Use of illicit drugs is common in non-affective psychosis (ICD-10 F20–29; (1)), usually 
seen in about half of the patients; 40–60%, ranging from 10 to 70% (2–9). Illicit drug use 
in psychosis has clinical implications and has been associated with more relapse and re-
hospitalizations, poorer social functioning, medication non-adherence, heightened suicide 
risk, increased treatment needs, and worse clinical outcomes (10–17). However, there are 
few clinical differences in relation to symptoms and family loading between drug-using and 
non-drug-using patients (18).
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There are opposing views on cannabis as a risk factor for psy-
chosis, however [see in Ref. (45) for an overview]. Some authors 
propose that there is a causal relationship between illicit drug use 
and non-affective psychosis (45, 46). Others suggest that illicit drugs 
only precipitate non-affective psychosis in vulnerable individuals 
on their pathway to psychosis (45–48). A variant of this is reversed 
causality; cannabis is used as a form of self-medication in psychosis, 
although existing data do not seem to support this hypothesis (38). 
Cannabis debut usually precedes onset of psychosis (10, 39, 49), 
e.g., by 7–8 years (50). However, most individuals do not develop 
psychosis after cannabis use, suggesting that risk of psychosis must 
be modulated by other factors. In line with this, data from recent 
comprehensive studies suggest that cannabis is an environmental 
risk factor interacting with more basic genetic and biological vul-
nerability for psychosis (51–53).
the effect of cannabIs on neurotransmItter systems
Tetrahydrocannabinol probably influences the endogenous can-
nabinoid and dopamine systems (23, 54, 55), via cannabinoid recep-
tors, which are distributed with high density in the cerebral cortex, 
including brain regions implicated in schizophrenia, and influence 
dopamine synthesis and uptake (23). Most studies on the neuro-
toxicity of THC in general are based on animal models, suggesting 
that THC increases dopamine levels in several regions of the brain, 
including striatal and prefrontal areas (56). Animal studies have 
also found more irreversible residual effects in prepubertal rats 
after chronic exposure to THC as compared to more mature rats 
(57). THC is a cannabinoid receptor 1(CB1) agonist, and Casadio 
et al. (58) suggest that cannabis produces its effects via the influence 
on CB1 receptors on GABA and glutamate, which modulate the 
excitability of midbrain dopamine neurons and prefrontal cortical 
pyramidal cells; it thus appears to switch off inhibitory inputs to 
dopamine neurons. THC may aggravate dopaminergic imbalances 
by increasing the dopaminergic tone in striatal regions of the brain, 
which, when administered repeatedly, decreases dopamine levels in 
prefrontal regions of the brain via sensitization processes resulting 
in expressions of a psychotic disorder (56, 59). It is possible that 
the repeated administration of THC alters the functioning of the 
prefrontal cortex by acting on dopamine signaling via activation 
of CB1 receptors. Kuepper et al. (56) argue for interpretative cau-
tion, however, since most evidence is based on animal research and 
the effects of endocannabinoids are not yet fully understood. No 
relationship between striatal postsynaptic dopamine receptors and 
cannabis use has also been reported (60), and pretreatment with 
the dopamine receptor antagonist haloperidol did not alter the 
behavioral effects of delta-9-THC (23). Bloomfield et al. (61) on 
the other hand found that chronic cannabis use was associated with 
reduced presynaptic dopamine synthesis capacity in the striatum, 
suggesting a complex relationship between cannabis and changes 
of dopamine availability.
In addition, there may be psychoactive substances in cannabis 
not yet studied, as there are at least 85 different cannabinoids in can-
nabis (62). Cannabidiol (CBD) may have a buffer effect against the 
negative effects of THC, e.g., Schubart et al. (63) found an associa-
tion between estimated CBD in cannabis and fewer web-based self-
reported experiences of psychotic symptoms. The CBD/THC ratio 
is possibly of importance for the psychological effects of  cannabis, 
Key concePt 2 | cannabis
The most widely used illicit drug worldwide; taken from the plant Cannabis 
sativa, and usually used as an illicit substance in the form of dried flower 
buds (marijuana), resin from the trichomes (hashish), or various extracts 
collectively known as hashish oil. Cannabis has psychological and cognitive 
effects, and can have psychosis-imitating properties.
Key concePt 1 | non-affective psychosis
A broader diagnostic group than schizophrenia only; includes schizophrenia-
spectrum psychosis, but not affective psychosis or drug-induced psychosis. 
The term reflects a more contemporary view of psychosis, e.g., as best 
reflected by a continuum.
Cannabis is the most widely used illicit drug in non-affective 
psychosis, and life-time cannabis use has typically been reported 
to be about 50% (2, 19–21). The rate of cannabis use disorder is 
somewhat lower; about every fourth patients with schizophrenia 
according to a recent meta-analysis by Koskinen et al. (22), with 
particularly high current and life-time rates in first-episode sam-
ples (28.6 and 44.4%, respectively). Cannabis is derived from the 
plant Cannabis sativa, and is usually used as an illicit substance 
in the form of dried flower buds (marijuana), resin from the tri-
chomes (hashish), or various extracts collectively known as hash-
ish oil. Cannabis has psychological and cognitive effects, and can 
have psychosis-imitating properties. These drug effects are usually 
attributed to cannabinoids, with delta-(9)-tetrahydrocannabinol 
(THC) as the main psychoactive substance influencing experience 
Key concePt 3 | tHc
Delta-(9)-tetrahydrocannabinol; a cannabinoid and the main psychoactive 
substance in cannabis, influencing experience and cognition.
and cognition (23). There is large intra-individual variability in 
the psychological reactions to THC, possibly related to individual 
differences in the corresponding brain activation changes (24). 
Psychosis-prone individuals, people with psychosis, and others who 
are genetically vulnerable to psychosis have an increased sensitivity 
to the adverse effects of THC (23).
cannabIs use as a rIsk factor for non-affectIve PsychosIs
Longitudinal studies have reported an increased likelihood for 
developing schizophrenia and other psychoses after cannabis use 
(25, 26), especially when cannabis use has been moderate to severe 
and/or is started in the early teens (27–29). Schizotopy has also 
been associated with cannabis use in a recent meta-analysis (30). 
In addition, several large-scale longitudinal studies have reported 
a relationship between cannabis use in adolescence as well as later 
symptoms of sub-threshold psychosis in the general population 
(31–37). The relationship between cannabis and psychosis seems 
fairly specific to schizophrenia, as compared to other mental disor-
ders (38–40), even though there are a relationship between symp-
toms of anxiety and cannabis (41). The relationship cannot be 
explained by potentially confounding factors such as premorbid 
disorders, other types of drug use, intoxication effects, personal-
ity traits, sociodemographic markers, or intellectual ability (40). 
Accordingly, several reviews conclude with an increased risk for 
psychosis in individuals who have used cannabis, typically in the 
magnitude of an odds ratio of 1.5–2 (20, 40, 42–44).
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suggesting that the increasingly popular THC-potent variants of 
cannabis (e.g., “skunk”) may be more psychosis-inducing. Finally, 
CBD has been under investigation in a few small clinical trials as a 
potentially novel antipsychotic agent, with equivocal results thus far 
and larger studies being needed (64). One promising study found 
CBD to be comparable in its antipsychotic effect to the antipsychotic 
amisulpride in a double-blind, randomized clinical trial in acute 
schizophrenia, and attributed the antipsychotic properties of CBD 
to its effect on the level of the endocannabinioid anandamide (65).
need for translatIonal knowledge
Thus, there is a high prevalence of cannabis use in non-affective 
psychosis with clinical implications. Early prospective longitudinal 
studies conclude that cannabis use is a risk factor for psychosis, and 
biochemical studies on cannabis have suggested potential mecha-
nisms for this effect. Recent advances in the field of neuroscience 
and genetics may have important implications for our understand-
ing of this relationship. Importantly, we need to better understand 
the vulnerability × cannabis interaction to shed light on the media-
tors of cannabis as a risk factor for psychosis in order to create 
targeted interventions; e.g., for whom is cannabis precarious? Thus, 
the present study reviews recent literature on vulnerability variables 
and/or mediating variables and cannabis, including data from our 
own laboratory. This includes focus on age of onset, cognition, 
brain functioning, family history, genetics, and neurological soft 
signs (NSS) in non-affective psychosis. Models will be presented 
to explain the findings. This review is also based on previous work 
by the present authors in Frontiers in Psychiatry (66); putting the 
work into a broader context and outlining the implications for 
scientific questions and issues within the field.
age of onset
Earlier psychosis debut – age of onset has been shown in patients 
who have been using cannabis (21, 67–71). However, some studies 
report no effect of illicit drug use on onset age (15, 72–74). The 
more adult psychosis was predicted by cannabis use at 15 versus 18 
years (32) and cannabis use at around 15 years or younger versus 
older debut (78). Furthermore, Schubart et al. (79) found very early 
that both cannabis use (under 12 years of age) and heavy cannabis 
use (>25 €/week) were associated with an increased likelihood 
of psychiatric hospitalizations. A recent study of 410 first-episode 
psychosis patients reported that those who had started cannabis 
at age 15 years or younger had an earlier onset of psychosis for 
about 2 years, and that the users of high-potency cannabis every-
day had the earliest psychosis onset (29). It is not possible to fully 
rule out, however, that the relationship between the development 
of psychosis and the younger age of cannabis debut is driven by 
a larger cumulative exposure to cannabis. Alternatively, early can-
nabis users may be the ones who have been using cannabis before 
the development of psychosis and thus cannabis could have been 
an actual risk factor for them. The older cannabis users, however, 
may have used cannabis more in parallel with the first signs of 
psychosis, hence clouding the dynamics of cannabis a risk factor. 
Still, transition to psychosis in an ultra-high-risk sample was found 
to be highest among those who started using cannabis before the 
age of 15 years and went on to frequent use (49).
The neurodevelopmental explanation is further substantiated 
by central brain development processes in adolescence that may 
be particularly sensitive to cannabis. Levels of endocannabinoids 
and cannabinoid receptors increase at this age, peaking at puberty 
(80). Furthermore, the endocannabinoid system is involved in key 
processes of brain maturation during adolescence, e.g., the control 
of neuronal specification and maturation (81). Thus, exposure to 
cannabis during critical neurodevelopmental stages may impact 
the maturation of the endocannabinoid system and other key 
neurotransmitter systems (58). Bossong and Niesink (55) suggest 
that cannabis use during adolescence results in the disturbance of 
certain local neural circuits within the prefrontal cortex, and that 
the disturbance occurs as an interaction between THC and the CB1 
receptors involved in the control of GABA and glutamate release. 
In line with this, studies have found that age at first use of cannabis 
predicted age at first psychotic symptom in patients with recent 
non-affective psychosis (50, 77, 82).
Our laboratory in Bergen, Norway, together with collaborating 
study organizations in Oslo and Stavanger, examined the effect 
of illicit drug use on onset age in a large sample of 1,119 patients 
with non-affective psychosis (83). Patients with illicit drug use had 
a significantly lower onset age of about 3 years compared with 
the abstinent group, primarily related to cannabis use and not to 
alcohol or other substances. This supports the notion that the effect 
of cannabis on age of onset is specific. As an overall conclusion, 
there is now evidence for an earlier onset age of psychosis in can-
nabis users often reported to be about 2–4 years. There are few 
studies suggesting that the earlier onset is related to early initia-
tion of cannabis use, e.g., before the age of 15 years and related to 
neurodevelopmental processes, but there may also be alternative 
explanations for this relationship.
cognItIon
A majority of patients with schizophrenia and non-affective psycho-
ses have clinically significant cognitive deficits (84–87). Cognitive 
deficits are vulnerability markers, present before the development 
Key concePt 4 | Age of onset
Age of psychosis debut, usually defined as the first psychotic breakthrough, 
defined by, e.g., a PANSS psychosis symptom item score of ≥4.
inconsistencies are possibly due to methodological differences and 
small sample sizes in several studies. Furthermore, some studies 
have used “first treatment contact” instead of first psychotic symp-
toms as an estimate for psychosis debut (69), which is sub-optimal 
since psychosis may last for several years before first treatment 
(75). Meta-analyses conclude, however, that there is an earlier onset 
age of psychosis in cannabis and polysubstance users compared 
with those without illicit drug use also when confounders have 
been controlled for (68, 76). In addition, there is an effect of THC 
dose – patients with a history of cannabis use had about 3 years 
earlier debut of psychosis, and the subjects who had been using 
high-potency cannabis everyday had the earliest onset (29).
The earlier onset age can possibly be attributed to the illicit drug 
use acting on the developing brain in adolescence (29, 32, 77). This 
neurodevelopmental hypothesis is also supported by a stronger 
relationship between adolescent cannabis use and psychosis as 
compared to adult use (27, 28). The effect of cannabis timing is 
also supported by longitudinal studies. As compared to non-users, 
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of psychosis (87, 88), in high-risk populations (89, 90), and which 
persist after treatment of clinical symptoms (91, 92). General 
 cognitive dysfunctions across cognitive domains are present, with 
additional selective deficits in working memory, executive function, 
attention, verbal fluency, episodic memory, and processing speed 
(93, 94). Typically, the impairment is between 1 and 2 SD, indicat-
ing a clinically significant loss of function (87, 95–98). Cognitive 
functioning is more important than positive psychotic symptoms 
in determining the patient’s functional outcome (93, 99–102).
There have been difficulties in drawing firm conclusions regard-
ing the long-term effects of cannabis on cognition, and studies 
should be interpreted with caution, however, due to often uncertain 
abstinence periods (103). Decrements in the ability to learn and 
remember new information in chronic users have been suggested, 
whereas other cognitive abilities are more unaffected, and younger 
cannabis users may be particularly vulnerable to these effects (104, 
105). This age affect is, however, not substantiated by many studies. 
Studies making a distinction between adolescence and adult debut 
have shown some cognitive decrements in early-onset cannabis 
users (106, 107).
Cannabis use may affect cognition differentially in psychosis. In 
a preliminary study in our laboratory, we examined the effects of 
cannabis on cognition in 31 patients with schizophrenia (19, 108). 
Surprisingly, we found that patients with schizophrenia who had a 
history of cannabis use scored significantly better than psychosis 
patients without cannabis use. This was found for almost all cog-
nitive domains investigated except learning; general intellectual 
ability, executive functions, attention, working memory, and psy-
chomotor speed. These results did not change when other illegal 
drugs where controlled for, and there were no differences in the 
two groups with regard to clinical variables (19). We hypothesized 
that there was less cognitive vulnerability in the cannabis group. 
Interestingly, other authors, such as Schnell et al. (109), also sug-
gested similar explanations at this point in time.
This finding prompted a review of the existing literature on the 
relationship between cannabis use and cognitive functioning in 
non-affective psychosis, and a systematic PubMed search resulted in 
23 studies (110). Fourteen of the studies reported that the cannabis 
groups showed better cognitive performance than the no-cannabis 
groups (19, 73, 108, 109, 111–120). Eight of the studies reported no 
or minimal differences in cognitive performance in the two groups 
(21, 121–127), and one study reported better cognitive performance 
in the no-cannabis compared with the drug group (128).
The results showed that most studies had found better cog-
nitive functioning in psychosis patients with cannabis use com-
pared with psychosis alone (110). This pattern has been found 
by other meta-analysis (112, 119, 129) and replicated by more 
recent studies (130, 131) as well as two meta-analyses (132, 133). 
There are also studies with contradictory findings, possibly due to 
methodological issues such as different definitions of drug abuse 
(110); there are methodological differences related to ongoing 
versus previous drug use, frequent versus infrequent use, younger 
age in drug groups, and differences in relation to test batteries 
and cognitive domains examined. However, superior cognitive 
functioning in the  drug-using group has been reported in first-
episode psychosis patients (131, 134) and at 10-year follow-ups 
after onset of psychosis (116). The meta-analysis by Yücel et al. 
(132) found that cannabis-using patients performed moderately 
better than non-using patients on measures of global cognition, 
visual memory, processing speed, working memory, planning, and 
reasoning. Rabin et al. (133) reported the following effect sizes for 
superior cognitive functioning in cannabis-using patient compared 
with non-using patients for each neurocognitive domains in their 
meta-analysis: general cognitive ability and intelligence 0.48; selec-
tive, sustained and divided attention 0.35; executive abilities 0.14; 
working memory and learning 0.07; retrieval and recognition 0.12; 
receptive and expressive language abilities 0.06; and visuospatial 
and constructional abilities 0.33; these thus show effect sizes in the 
small to moderate range.
To explain the different cognitive profiles, we hypothesized 
that there was less cognitive vulnerability in the cannabis group; 
their psychosis breakthrough was related to aberrant information 
processing due to cannabis-induced transient cognitive deficits. 
To test this, we first performed a preliminary prospective study 
of 31 patients with acute psychosis, assessing cognitive function 
at admission to a psychiatric emergency ward, after 6 weeks and 
after 3 months. The patients with both cannabis history and psy-
chosis showed a significantly larger improvement in their cognitive 
performance in the 3 months after admission compared with the 
psychotic patients without cannabis use (108).
In a continuation of this study, we improved the design by focus-
ing on the period when the patients were in-patients to control for 
the illicit drug use after admission to the acute ward in a total sam-
ple of 123 patients (135, 136). The patients were examined by the 
Battery for the Assessment of Neuropsychological Status (RBANS) 
with alternative forms to minimize practice effects (95, 137, 138) 
at baseline and follow-up (mean time to follow-up 4 weeks). As 
expected, the cannabis-using group showed the largest improve-
ment in cognition, especially among the youngest patients. This 
suggests that indeed cannabis use did induce transient cognitive 
deficits in the cannabis-using psychosis group, and that younger 
patients could have a larger capacity for restoring their cognitive 
capability. Thus, overall, there seems to be less persistent cognitive 
deficits in patients with psychosis and cannabis use, indicating less 
neurocognitive vulnerability.
braIn functIonIng
Reviews of structural brain imaging studies in non-affective psy-
chosis, usually by means of magnetic resonance imaging (MRI) 
paradigms, have shown several distinct alterations in gray matter 
Key concePt 5 | cognitive deficits
Reduced ability or capacity for mental information processing; in non-affective 
psychosis often seen as problems in the following areas: attention/vigilance, 
working memory, learning, executive functioning, perceptual processing, 
visuomotor speed, and verbal fluency.
Key concePt 6 | Brain imaging
Techniques to image the structure and function of the brain, typically by 
means of magnetic resonance imaging (MRI) and functional magnetic 
resonance imaging (fMRI). There are also other brain-imaging techniques.
and white matter, both widespread and, in some studies, progressive 
changes (139). Voxel-based-morphometry (VBM) has, according to 
a review, most consistently shown volume reduction in the superior 
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temporal cortex in chronic patients, and in frontal brain regions 
in first-episode and high-risk individuals (140). Functional brain 
imaging studies, often by means of functional MRI (fMRI), find 
abnormal communication between and/or integration of brain 
activation in local and distributed circuits (141–143), and con-
nectivity deficits and additional transient states of hyper- and/or 
hypo-connectivity related to specific tasks (142). Decreased brain 
activation to effort-demanding tasks is a typical finding in non-
affective psychosis (144–147), and lately several studies have shown 
increased brain activation in the default mode network (which 
includes activation in the medial prefrontal and temporal lobes 
reflecting endogenous generated thought) in psychosis compared 
with normal controls (147–150).
Studies have mostly been inconclusive in regard to the effect 
of long-term exposure to cannabis on the brain, but some brain 
imaging studies have found effects of long-term heavy use on gray 
matter volume (151–154). Mata et al. (155) suggested that normal 
neurodevelopment was affected after observing gyrification abnor-
malities in the cortex after long-term use. Long-term cannabis use 
has also been found to affect white matter as measured by diffusion 
tensor imaging (DTl), e.g., in the corpus callosum (156). Bossong 
et al. (157) recently reviewed neuroimaging studies on the long-
term and acute effects of cannabis in both adult and adolescents on 
brain function related to learning and memory functions. Cannabis 
did not affect performance, but there were subtle changes in brain 
activation patterns in the cannabis-using group – both acute and 
long-term effects. The authors concluded that there was increased 
activity and a higher level of deactivation in the cannabis groups, 
and attributed this to compensatory increased or changed neural 
effort or non-cognitive factors like cerebral perfusion; however, 
they also pointed to the methodological problems related to com-
paring the studies.
Structural MRI and DTI studies comparing psychoses with and 
without cannabis use have shown less altered (134, 158), more 
anomalous (159–164), and equivalent (165–167) brain anatomy 
in the cannabis group, thus making firm conclusions difficult. 
Ongoing, long-term, and heavy use may influence the results: the 
continuation of cannabis use was found to increase gray matter 
loss and lateral and third ventricle enlargement after 5 years (161), 
and users of more than five joints daily for more than 10 years 
were shown to have bilaterally reduced hippocampal and amygdala 
volumes (168). A systematic review of 15 MRI and 4 post-mortem 
studies found evidence for brain structural abnormalities after can-
nabis use in psychosis in CB1-rich areas of the brain-like cingu-
lum, the dorsolateral prefrontal cortex, and the cerebellum, and the 
authors suggested that the effect of cannabis is actually more distinct 
in psychosis than in the normal controls (154). Smith et al. (169) 
compared healthy controls, subjects with a history of cannabis use 
disorder, schizophrenia only, and both schizophrenia and a history 
of cannabis use disorder, while subjects with recent cannabis use 
were excluded. Both cannabis groups showed differences in relation 
to WM-related subcortical morphology, and the authors attributed 
this to either chronic cannabis abuse or the presence of biomarkers 
that characterize a vulnerability to the effects of cannabis.
There have been too few fMRI studies on long-term cannabis 
use and non-affective psychosis to reach a conclusion. One study, 
however, reported that schizophrenia patients with substance-use 
history showed increased cerebral activation to passive view-
ing of emotionally negative pictures, and concluded that the 
medial prefrontal cortex functioning is more preserved in dual-
diagnosis schizophrenia (170). Potvin et al. (171) also found less 
impaired brain functioning during socio-emotional processing 
in patients with a dual diagnosis (mainly cannabis users) than 
schizophrenia alone.
To further examine brain functioning in cannabis use and psy-
chosis, we conducted a study at our laboratory (66) to examine 
brain activation in 26 patients with schizophrenia with and with-
out a history of previous cannabis use by using an fMRI para-
digm comparing task-dependent (effort mode network) [cf. Ref. 
(172)] and task-independent (default mode network) [cf. Ref. 
(173)] conditions. We expected to replicate the better cognition 
for the cannabis users by finding less-anomalous brain activation 
patterns in the previous cannabis group, defined as the ability to 
up-regulate the effort mode network during the task-dependent 
condition [dichotic listening task with attention instructions, see 
in Ref. (174)] and down-regulate the default mode network dur-
ing the task-independent condition. The present sample did all 
have a history of cannabis abuse as the main drug of choice, but 
not within the last 6 months, and patients that had been using 
meth-amphetamine, cocaine or opiates were excluded. The study 
showed different activation patterns for the task-dependent and 
task-independent conditions, essentially following the effort and 
default mode networks, respectively. Although all patients showed 
similarities across activation patterns, group differences emerged 
in the intensity and extension of the activation patterns that could 
not be explained by differences in clinical or demographic vari-
ables. The activation was more pronounced for the task-dependent 
condition in the cannabis group, while it was more pronounced 
for the task-independent condition in the no-cannabis group. 
Thus, as hypothesized, the previous cannabis group managed to 
up-regulate the effort mode network during the task-dependent 
condition and down-regulate the default mode network during the 
task-independent condition to a larger extent than the no-cannabis 
group. The no-cannabis group did show a pattern closer to the 
typical schizophrenia findings [see in Ref. (147)], indicating more 
impaired brain activation, and supporting less-anomalous brain 
activation in cannabis psychosis (66).
Two later studies have similar findings of better brain function-
ing for cannabis users. Patients with dual diagnosis of cannabis 
abuse and schizophrenia were found to be less impaired relative 
to schizophrenia only compared with healthy controls in regard 
to emotional memory and prefrontal lobe functioning (175), and 
showed a more normalized brain activation pattern during mental 
rotation in the left superior parietal region relative to schizophrenia 
only compared with healthy controls (176). It must be noted, how-
ever, that the differences between the different groups are subtle in 
most studies, and even group-based differences between normal 
controls and patients with schizophrenia and non-affective psy-
chosis are usually subtle and of unclear clinical relevance. Still, it 
can be concluded that there are some data, although scarce, sug-
gesting minor long-term effects of cannabis on brain structure in 
psychosis patients, but that the majority of studies show better 
brain functioning in this group, suggesting less neurocognitive 
vulnerability.
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risk in people with certain genetic or environment vulnerabilities. 
Verdoux (185) found that subjects with established vulnerability 
for psychoses showed a stronger risk for psychosis after canna-
bis use than individuals without such vulnerability. Still, a study 
observed that cannabis also increased the risk for schizophrenia 
when family history was controlled for (78). In addition, cannabis 
interacts with other environmental risk factors like developmen-
tal trauma and child maltreatment, minority group position, and 
growing up in an urban environment, increasing the risk even 
further with the increasing number of risk factors (51, 59, 186). 
Also, certain variants of the COMT gene gave an increased risk 
for psychotic experiences after exposure to both cannabis use and 
childhood maltreatment (187, 188). It has been suggested that the 
environmental risk factor may induce differential sensitivity to 
cannabis (59). Recent animal models suggest long-lasting epige-
netic changes after early negative life events (189), thus epigenetic 
mechanisms may increase the vulnerability to cannabis in certain 
individuals.
Summing up, there seems to be some familiar and genetic 
vulnerability present in non-affective psychosis with cannabis 
use, possibly modified by environmental risk factors, that may 
be acting on neurotransmitter systems and/or genetic expression 
that particularly sensitize the individual to cannabis, but there 
are also less vulnerability markers such as NSS, cognitive defi-
cits and probably brain abnormalities than in psychosis without 
cannabis use.
dIscussIon
crItIcal remarks
There are inconsistencies – not all studies find better cognition 
or less-disturbed brain functioning in cannabis-using patients. 
An important variability in the methodology of the studies may 
explain this, e.g., the different definitions of cannabis use, current, 
life-time or previous use, or a cannabis use disorder. Previous use, 
before the development of psychosis, is most relevant for the effects 
of cannabis within a vulnerability framework (110). It is also 
important to rule out the potential confounding effects of canna-
bis intoxication or recent cannabis use on, e.g., brain functioning 
seen in some studies (190–192). Recently, a large cross-sectional 
study compared the effect of current cannabis use and the effect of 
life-time cannabis use in 956 patients. This study concluded that 
there was a short-term negative effect of recent cannabis use on 
cognition and in contrast a positive long-term effect of life-time 
use, suggesting that the life-time cannabis-using group formed a 
subgroup with a different cognitive profile (193). Furthermore, 
some studies exclude patients not meeting the diagnostic criteria 
of a substance-use disorder, biasing the drug groups to consist of 
quite heavy users, and there are even studies where the no-drug 
group includes patients with previous drug use [see Ref. (122)].
Although cannabis as a risk factor for psychosis is quite 
established, there are unresolved issues. Epidemiologically, it is 
hard to explain that there is no great increase in the prevalence 
of non- affective psychosis in light of the increasing use of can-
nabis in  several countries, even though a few authors argue that 
this is indeed the case (194). Furthermore, most patients do start 
using cannabis before psychosis breakthrough (73, 195–197). But 
other varIables medIatIng neurobIologIcal 
vulnerabIlIty
neurologIcal soft sIgns
Neurological soft signs are subtle sensory and motor performance 
anomalies that serve as markers of sub-optimal  neurological 
 development – there is an excess of NSS already evident in first-
Key concePt 7 | neurological soft signs
Subtle sensory and motor performance anomalies that serve as markers of 
a sub-optimal neurological development.
episode psychosis (177). Fewer NSS have been observed in schizo-
phrenia with cannabis use than without cannabis use (74, 116, 160, 
178). Ruiz-Veguilla et al. (178) reported an association between 
high NSS and not having been a heavy cannabis user and a family 
history of psychosis, and suggested a potentially different pathway 
to psychosis in relation to cannabis use. Less NSS in cannabis psy-
chosis indicates less neurobiological vulnerability.
famIly hIstory and genetIcs
Family history of serious mental disorders is often used as a proxy 
for genetic vulnerability (179). Proal et al. (180) reported that those 
who developed schizophrenia after cannabis use in adolescence 
had the same family history of schizophrenia as patients without 
cannabis use.
A few studies have examined the effects of polymorphisms in 
candidate genes on cannabis use and psychosis. In a longitudinal 
study, an interaction between the valine versus methionine allele 
of the Catechol-o-methyltransferase (COMT) gene and adolescent 
cannabis use significantly increased the likelihood of psychosis (27). 
This finding has not been replicated by all studies (179), however; 
Zammit et al. (181) did not find an effect of cannabis use on psy-
chosis according to variation in COMT alleles, but an interaction 
between the COMT alleles and sensitivity for psychosis and cog-
nitive effects of THC has been replicated by Henquet et al. (182, 
183). There are also other genes, influencing D2 receptors and the 
cannabinoid system, that have been found to modify the sensitiv-
ity to cannabis. Certain variant (C/C genotype) of the AKT1 gene 
has been shown to give an increased likelihood of psychosis after 
life-time cannabis use (29), and looking at schizotypy proneness in 
unaffected siblings, Van Winkel and Genetic Risk and Outcome of 
Psychosis (GROUP) Investigators (52) found that genetic variation 
in AKT1 mediated both short-term as well as longer-term effects 
associated with use of cannabis.
This indicates a gene × environment interaction (179); there 
is possibly a genetically based sensitivity to substances (59), con-
sistent with the fact that most people do not develop psychosis 
Key concePt 8 | Gene × environment interaction
The interaction between genetic vulnerability and environmental risk factors 
for psychosis, exemplified by the notion of a genetically based sensitivity to 
illicit substances such as cannabis.
after cannabis use. Parakh and Basu (184) reviewed evidence on 
the association between cannabis and psychosis and concluded 
that cannabis is a component cause of psychosis, increasing the 
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of vulnerability in cannabis psychosis and no-cannabis  psychosis, 
both groups having more general genetic vulnerability, while the 
cannabis pathway to psychosis has less neurobiological vulner-
ability. This can reflect two alternative models; (1) less specific 
vulnerability factors for psychosis, or (2) less general vulnerability.
The first model (see model 1 in Figure 1) suggests that cannabis-
using psychosis patients have an unspecific vulnerability for mental 
disorder in general, explaining the family loading results. There are, 
e.g., several findings on the unspecific family loading in mental 
disorders; almost any psychiatric disorder in first-degree relatives 
is associated with an increased risk of schizophrenia (59), and there 
seems to be a partly shared genetic underpinning behind several 
mental disorders (204). These could be related to specific domains 
of risk phenotypes suggested by Van Os et al. (59) such as affec-
tive dysregulation. Childhood trauma and maltreatment may also 
be unspecific to psychosis [see in Ref. (205)]. Cognitive dysfunc-
tion, sub-optimal brain functioning, and NSS are more specific to 
non-affective psychosis, and may constitute a more illness-specific 
vulnerability marker, seen in the more typical non-cannabis-using 
psychotic patients.
Still, a breakdown of information processing is central to the 
development of psychosis (87). Cannabis use of sufficient mag-
nitude, or in individuals particularly vulnerable to the effects of 
cannabis, may lead to transient compromised brain functioning, 
causing a breakdown of reality testing (135, 136). These changes 
can cause psychosis for some individuals, but will normally not 
cause the characteristic persistent cognitive impairments seen in 
psychosis. Thus, cannabis is viewed as an environmental factor 
imitating the effect of the typical neurobiological vulnerability (54). 
In line with this, cognitive improvement was shown in those who 
stopped using cannabis (206).
An alternative model (see model 2 in Figure 1) could be illus-
trated by using the classical stress–vulnerability framework (207, 
208); the tendency to develop psychosis is a function of vulner-
ability × stress. When cannabis is entered into the equation as a 
stress factor, the need for a high vulnerability load is decreased. 
More cannabis x less vulnerability generates a tendency to develop 
psychosis that is similar to less cannabis × high vulnerability. The 
less vulnerability load is primarily of neurobiological origin and is 
shown by fewer lasting cognitive deficits, fewer brain abnormali-
ties, and fewer NSS.
concludIng remarks
Cannabis is a risk factor for non-affective psychosis, interacting with 
genetic and environmental vulnerability. Patients with cannabis use 
have fewer cognitive deficits, probably fewer brain abnormalities, 
and fewer NSS, but at the same time genetic loading and family 
history of mental illness comparable to other patients with non-
affective psychosis. It is suggested that the pathway to psychosis via 
cannabis is less influenced by neurobiological vulnerability factors. 
Better knowledge of vulnerability profiles in those sensitive to can-
nabis could help us detect individuals for whom cannabis is more 
precarious. At this point, it can be speculated that young people 
with family loading of mental illness, and sub-threshold positive 
symptoms indicating a more general psychosis risk, should be care-
ful with cannabis – the last point is especially relevant for early 
intervention services. Thus, the presence of such markers may sug-
 developmental processes related to the disorder itself can theo-
retically influence the inclination to take drugs, and this is hard 
to test empirically.
Theoretically, there may be alternative explanations for the 
better brain and cognitive functioning in cannabis psychosis, e.g., 
superior social skills among those with cannabis psychosis, making 
users “skillful” enough to get hold of illegal drugs. Superior social 
skills are not consistent with the finding of poorer prognosis in 
this group. To our knowledge, few longitudinal studies have exam-
ined this directly and the issue remains unresolved. Two studies 
reported poorer premorbid functioning in psychosis patients who 
also used illegal drugs (198), and better premorbid social func-
tioning and poorer premorbid academic functioning in this group 
(199), respectively.
Understanding the path to psychosis via cannabis also needs 
to take into account complex psychological and motivational 
processes. Griffith-Lendering et al. (200) assessed self-reported 
thought problems, social problems, attention problems, and can-
nabis use at different time points during adolescence. Cannabis 
use predicted psychosis vulnerability and vice versa, suggesting a 
bidirectional relationship between these variables, even though the 
concept of self-medicating is misleading due to cannabis’ negative 
influence on symptomatology (201). Using a time-sampling tech-
nique, daily life cannabis use was shown to predict a more acute 
decrease in negative affect but also sub-acute increased levels of 
hallucinatory experiences in patients than controls, suggesting a 
vicious circle of deleterious use in these patients (201). In-depth 
interviews showed that the patients themselves reported change 
over time in their experience of cannabis, cannabis use preceded 
mental health for all; cannabis use was fun at first, but the experi-
ence changed over time to more addiction-based behavior and 
more frightening experiences, but also parallel positive experiences 
for some (202).
vulnerabIlIty models to exPlaIn the fIndIngs
Taken together, there are now findings from studies on age of onset, 
cognition, brain functioning, NSS, and family history that together 
make a pattern. Compared with non-using non-affective psychosis, 
the present review shows that there seems to be less stable cogni-
tive deficits in patients with cannabis use and psychosis, in addi-
tion to less NSS and possibly more normalized brain functioning, 
indicating less neurobiological vulnerability for psychosis. There 
is, however, some familiar and genetic vulnerability for psychosis 
present in the cannabis psychosis group. The familiar and genetic 
vulnerability may possibly influence the cannabis pathway to psy-
chosis by acting on the neurotransmitter systems that may be par-
ticularly sensitive to cannabis, with several recent comprehensive 
literature reviews supporting this conclusion (45, 51, 55, 56, 58, 
179, 184, 186, 203).
This gene–environment interaction does not, however, integrate 
the seemingly paradoxical findings of both less vulnerability mark-
ers and some genetic vulnerability. Bloomfield et al. (61) also sug-
gested that cannabis increased the risk of psychosis by a different 
mechanism than typically seen in schizophrenia after examining 
dopamine synthesis capacity in the striatum. Furthermore, an ear-
lier age of onset suggests a different pathway to psychosis in canna-
bis-using patients. It can be speculated that there are different levels 
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gest to the  clinician that these patients may be particularly sensitive 
to cannabis. At the same time, the patients that develop psychosis 
after a period of cannabis use may have less neurobiological vulner-
ability. They may to a larger extent be able to recover their cognitive 
abilities if they are abstinent from illicit substances, with positive 
implications for the rehabilitation process and work capacity. In 
addition, it can also be argued that a general public warning about 
the age effect of cannabis use and the effect of high THC content 
could be put forward, but existing research does not directly test this.
FiGure 1 | two alternative models for differential pathways to non-affective psychosis as a result of cannabis use and vulnerability profile.
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